Single-Dose LSD Medication Reduces Generalized Anxiety in Phase 2B Trial

Recent phase 2b clinical trials of MM120, a pharmaceutical formulation of LSD developed by MindMed, demonstrate significant promise as a treatment for moderate-to-severe generalized anxiety disorder (GAD). The studies revealed that a single 100 microgram dose of MM120 led to a substantial 7.6-point reduction in anxiety scores by week four, with 65% of patients showing clinical response and 48% achieving remission sustained to week 12. MM120's efficacy appears to arise from its capacity to enhance neuroplasticity, facilitating profound and meaningful experiences that contribute to durable improvements in anxiety and depression symptoms. Despite the prevalence of GAD affecting approximately 26 million adults in the U.S. and limited effective treatments since 2007, MM120 received FDA Breakthrough Therapy Designation, highlighting its potential to fill this therapeutic gap. The trials were conducted under rigorous, placebo-controlled, double-blind protocols, with observed rapid symptom improvement starting within the first week and maintained over three months. While side effects such as hallucinations, nausea, and headaches were noted, the 100 microgram dose was identified as optimal, with higher or lower doses showing less consistent benefits.